Bolt Projects Surges Post-Merger, Reports $149.6M Profit Amid Cash Flow Concerns

Introduction

Bolt Projects Holdings Inc (NASDAQ: BSLK) is a biotechnology-driven materials company that develops nature-inspired solutions for the fashion, beauty, and personal care industries. Headquartered in Berkeley, California, the firm applies advances in biotechnology and artificial intelligence to cultivate biomaterials designed to replace petroleum-based polymers and non-biodegradable ingredients. Its focus is on scaling sustainable alternatives derived from yeast, sugar, salt, and water, with an emphasis on reducing environmental impact in high-volume consumer goods.

Corporate Structure

Founded in 2009, Bolt Projects Holdings operates with a team of approximately 11–50 employees, according to its LinkedIn profile. Leadership includes scientists and engineers with advanced degrees, such as CTO David Breslauer, PhD, who specializes in recombinant polymers and silk technologies. The company’s intellectual property portfolio comprises 49 granted patents and 171 pending applications, reflecting over a decade of research and development.

Biomaterials by Pawel Czerwinski

Developments and News

On August 13, 2024, Bolt Threads finalized its business combination with Golden Arrow Merger Corp (Nasdaq: GAMC). Effective August 14, 2024, the combined entity began trading on the Nasdaq under the ticker BSLK. CEO Dan Widmaier and Golden Arrow board chairman Jacob W. Doft discussed the transition as a means to scale the company’s biomaterials platform.

In its earnings report for the twelve months ended September 30, 2024, Bolt Projects reported a net profit of US$149.6 million but recorded negative free cash flow of US$19 million, resulting in an accrual ratio of 141.6. Analysts noted that unusual non-cash charges totaling US$64 million affected statutory profit, and they emphasized the potential for a return to stronger cash conversion as a priority for shareholders.

On March 8, 2024, the company filed a Form 15-12G with the SEC to terminate its prior registration under Section 12(g) following its merger with Biscuit Parent, LLC. Earlier, on February 29 and 28, 2024, two SC 13D/A amendments disclosed that major venture capital investors—Foundry Venture Capital 2013, L.P. and Madrona Venture Fund IV, LP—held no beneficial ownership as of February 26 and 27, respectively.

Financial and Strategic Analysis

As of July 17, 2025, BSLK shares are priced at US$4.08, reflecting an 84.62 percent increase on a volume of 17,991,002 traded on the Nasdaq. The company’s strategic focus remains on commercializing its flagship product, b-silk™, a fully biodegradable protein polymer aimed at replacing silicone elastomers in personal care formulations. Bolt Projects aims to address both regulatory and consumer pressures on microplastics and synthetic polymers, leveraging partnerships with brands such as Vegamour and Kelly Slater’s Freaks of Nature sunscreen.

The difference between net profit and free cash flow highlights the importance of monitoring cash conversion. With substantial patent coverage and a growing customer base in beauty and fashion applications, management is positioned to seek operational efficiencies and revenue growth that align profit recognition with cash inflows.

Market Position and Industry Context

Bolt Projects operates at the intersection of synthetic biology and green chemistry, targeting the sizable beauty and personal care market, which is under increasing scrutiny for its environmental impact. By creating biobased, biodegradable ingredients, the company addresses demand for sustainable alternatives to petroleum-derived polymers. Competitors in the biomaterials space include firms developing plant-derived polymers and fermentation-based ingredients. Bolt Projects’ emphasis on spider silk-inspired proteins and its patent portfolio aim to differentiate it within this sector.

tl;dr

On August 14, 2024, Bolt Projects Holdings Inc began trading as BSLK following its merger with Golden Arrow Merger Corp. As of July 17, 2025, shares trade at US$4.08, up 84.62 percent on high volume. The company reported US$149.6 million in net profit for the year ending September 30, 2024, but recorded negative free cash flow of US$19 million, influenced in part by US$64 million of unusual non-cash charges. Bolt Projects continues to commercialize its b-silk™ biomaterial in beauty and personal care, supported by 49 granted patents and 171 pending applications while targeting improved cash conversion in the future.